Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC)

被引：0
|
作者：
Taylor, Melissa
Reddy, Shilpa
Kumar, Prashanth Ashok
Hariri, Dana
Sokol, Ethan
Sivakumar, Smruthy
Quintanilha, Julia
Pavlick, Dean
Levy, Mia Alyce
Ross, Jeffrey S.
Lustberg, Maryam B.
机构：
[1] Yale New Haven Hosp, New Haven, CT USA
[2] Upstate Univ Hosp, Syracuse, NY USA
[3] SUNY Upstate Univ Hosp, Syracuse, NY USA
[4] Fdn Med Inc, Cambridge, MA USA
[5] Fdn Med Inc, Boston, MA USA
[6] Fdn Med, Cambridge, MA USA
[7] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1092
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Analysis of 47 Patients with Triple Negative (ER, PGR, HER2) Breast Cancer
    Gunes, Mehmet Emin
    Celik, Gurhan
    Trabulus, Fadime Didem
    Aksoy, Sefika
    Ozoran, Emre
    Aren, Acar
    Gucin, Zuhal
    Bahadir, Fadime
    ISTANBUL MEDICAL JOURNAL, 2012, 13 (04): : 166 - 168
  • [42] DIFFERENCES IN METASTATIC POTENTIAL IN HER2 POSITIVE AND TRIPLE NEGATIVE INFLAMMATORY BREAST CANCER
    Kolarevic, Daniela
    Tomasevic, Zorica
    BREAST, 2011, 20 : S38 - S39
  • [43] Patients with HER2 Positive or Triple Negative Breast Cancer (TNBC) Treated with Neoadjuvant Chemotherapy Who Achieve a Breast Pathologic Complete Response have Low Rate of Nodal Positivity
    Barron, A. U.
    Hoskin, T.
    Day, C.
    Boughey, J. C.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S25 - S25
  • [44] Assessment of HER2 status in breast cancer
    Penault-Llorca, F
    Cayre, A
    BULLETIN DU CANCER, 2004, 91 : S211 - S215
  • [45] Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status
    Cha, Chihwan David
    Kim, Kyung Eun
    Kim, Jungbin
    Um, Eunhae
    Choi, Nayeon
    Lee, Jungsun
    Gwak, Geumhee
    Kim, Jae Il
    Chung, Min Sung
    NPJ BREAST CANCER, 2025, 11 (01)
  • [46] Accurate assessment of HER2 status in "triple-negative" breast cancer requires both IHC and FISH testing
    Ren, Q.
    Alexander, M.
    Samdani, R.
    Singh, B.
    CANCER RESEARCH, 2013, 73
  • [47] Deciphering the Clinicopathological, Immunological and Molecular Profile of HER2 Low Breast Cancer within Luminal and Triple-negative Breast Cancer
    Atallah, N.
    Rakha, E.
    JOURNAL OF PATHOLOGY, 2023, 261 (SUPPL1) : S18 - S18
  • [48] The impact of low HER2 expression on clinical significances and outcomes in patients with HER2-negative early breast cancer
    Koi, Y.
    Tajiri, W.
    Kawasaki, J.
    Akiyoshi, S.
    Koga, C.
    Nakamura, Y.
    Taguchi, K.
    Tokunaga, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S311 - S312
  • [49] Accurate assessment of HER2 status in 'triple-negative' breast cancer requires both IHC and FISH testing
    Ren, Q.
    Samdani, R.
    Singh, B.
    HISTOPATHOLOGY, 2012, 61 : 29 - 29
  • [50] Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, T.
    Solomayer, E.
    Uhr, J.
    Wallwiener, D.
    ONKOLOGIE, 2008, 31 : 51 - 51
12345